87 Patents
- 0 cites
- 0 cites
- US125530642026Methods and Compositions for Targeted Genetic Modification Through Single-step Multiple Targeting
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US125437112026Non-human Animals Expressing Ph-sensitive Immunoglobulin Sequences
Regeneron Pharmaceuticals, Inc
0 cites - 0 cites
- 0 cites
- 0 cites
- 0 cites
- 0 cites
- 0 cites
- US124599912025Compositions and Methods for Using Bispecific Antibodies to Bind Complement and a Target Antigen
REGENERON PHARMACEUTICALS, Inc.
0 cites - 0 cites
- US124417972025Anti-fc Ε-r1 Α (fcϵr1α) Antibodies, Bispecific Antigen-binding Molecules That Bind Fcϵr1α and CD3, and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US124418002025Bispecific Anti-psma X Anti-cd28 Antibodies and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US124332652025Non-human Animals Having a Humanized a Proliferation-inducing Ligand Gene
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US124332642025Non-human Animals Having an Engineered Immunoglobulin Lambda Light Chain Locus
Regeneron Pharmaceuticals, Inc.
0 cites - US124145512025Genetically Modified Major Histocompatibility Complex Mice
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US124045052025Delivery of a Gene-editing System with a Single Retroviral Particle and Methods of Generation and Use
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- 0 cites
- US123898882025Mice Expressing a Limited Immunoglobulin Light Chain Repertoire
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US123765732025Genetically Modified Mice Comprising Humanized Cellular Immune System Components with Improved Diversity of TCRB Repertoire
Regeneron Pharmaceuticals, Inc.
0 cites - US123714752025Nucleic Acids Encoding Anchor Modified Antibodies and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US123715032025Methods of Treatment Using a Leptin Receptor Agonist Antibody
REGENERON PHARMACEUTICALS, Inc.
0 cites - 0 cites
- 0 cites
- US123428012025Methods for Producing Antigen-binding Proteins Against Foreign Antigens
Regeneron Pharmaceuticals, Inc.
0 cites - US123381992025Bis-octahydrophenanthrene Carboxamides and Protein Conjugates Thereof
REGENERON PHARMACEUTICALS, Inc.
0 cites - 0 cites
- 0 cites
- US122953542025Non-human Animals Expressing Exogenous Terminal Deoxynucleotidyltransferase
Regeneron Pharmaceuticals, Inc.
0 cites - US122811732025Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- 0 cites
- 0 cites
- 0 cites
- US122091802025Bis-octahydrophenanthrene Carboxamide Derivatives and Protein Conjugates Thereof for Use as LXR Agonists
REGENERON PHARMACEUTICALS, Inc.
0 cites - US121610972024Non-human Animals Having a Humanized Signal-regulatory Protein Gene
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US121275372024Genetically Modified Non-human Animals and Methods of Use Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US120967542024Non-human Animals Having a Humanized Lymphocyte-activation Gene 3
Regeneron Pharmaceuticals, Inc.
0 cites - US120895752024Genetically Modified Mouse That Expresses Humanized PD1 and PD-L1 Proteins
Regeneron Pharmaceuticals, Inc.
0 cites - US120901932024Glucagon-like Peptide 1 Receptor Agonists and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- 0 cites
- 0 cites
- 0 cites
- US120362882024Methods of Using Humanized Fcγr Mice to Assay Fc Regions
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- US119640162024Combination of IL-4/IL-13 Pathway Inhibitors and Plasma Cell Ablation for Treating Allergy
REGENERON PHARMACEUTICALS, Inc.
0 cites - 0 cites
- 0 cites
- 0 cites
- 0 cites
- US118916182024Mouse Comprising a Humanized TTR Locus with a Beta-slip Mutation and Methods of Use
Regeneron Pharmaceuticals, Inc.
0 cites - US118665032024Methods for Treating Inflammatory Conditions of the Airway or Lungs by Administering Antagonist Monoclonal Antibodies to Interleukin-33 and Interleukin-4 Receptor
Regeneron Pharmaceuticals, Inc.
0 cites - US117796332023Glucagon-like Peptide 1 Receptor Agonists and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US117789952023Genetically Modified Non-human Animals and Methods of Use Thereof
Institute For Research In Biomedicine (IRB)
0 cites - 0 cites
- US117660322023Genetically Modified Non-human Animals Expressing Human EPO
Institute For Research In Biomedicine (IRB)
0 cites - 0 cites
- US116978282023Methods and Compositions for Targeted Genetic Modification Using Paired Guide Rnas
Regeneran Pharmaceuticals, Inc.
0 cites - US116840502023Non-human Animals Having a Humanized Programmed Cell Death 1 Gene
Regeneran Pharmaceuticals, Inc.
0 cites - US116660402023Humanized Non-human Animals with Restricted Immunoglobulin Heavy Chain Loci
Regeneron Pharmaceuticals, Inc.
0 cites - US116423902023Method of Treatment with a Fusion Protein Comprising Apelin and an Anti-aplnr Antibody
Regeneran Pharmaceuticals, Inc.
0 cites - 0 cites
- 0 cites
- 0 cites
- US116083812023Methods of Treatment Using a Leptin Receptor Agonist Antibody
REGENERON PHARMACEUTICALS, Inc.
0 cites - 0 cites
- US115769842023Genetically Modified Mouse with Humanized Immunoglobulin Heavy Chain Constant Region Genes and Method of Using
Regeneron Pharmaceuticals, Inc.
0 cites - US115781272023Anti-fc Epsilon-r1 Alpha (fcεr1α) Antibodies, Bispecific Antigen-binding Molecules That Bind Fcεr1α and CD3, and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US115781352023Multispecific Antigen-binding Molecules Binding to a Target and an Internalizing Effector Protein That Is CD63 and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - US115763562023Genetically Modified Non-human Animals and Methods of Use Thereof
Institute For Research In Biomedicine (IRB)
0 cites - US115590502023Humanized Non-human Animals with Restricted Immunoglobulin Heavy Chain Loci
Regeneron Pharmaceuticals, Inc.
0 cites - US115489472023Bispecific Anti-psma X Anti-cd28 Antibodies and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites